Eli Lilly and Company
$921
▲
1.99%
2026-04-22 10:12:13
www.lilly.com
NYQ: LLY
Explore Eli Lilly and Company stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$868.52 B
Current Price
$921
52W High / Low
$1,133.95 / $623.78
Stock P/E
40.12
Book Value
$29.66
Dividend Yield
0.75%
ROCE
38.44%
ROE
1.01%
Face Value
—
EPS
$22.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
50,000
Beta
0.5
Debt / Equity
165.31
Current Ratio
1.58
Quick Ratio
1.19
Forward P/E
22.33
Price / Sales
12.9
Enterprise Value
$875.94 B
EV / EBITDA
27.64
EV / Revenue
13.44
Rating
Buy
Target Price
$1,209.21
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Leverage is relatively high.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Bristol-Myers Squibb Company | $59.38 | 17.16 | $121.36 B | 4.26% | 20.6% | 40.44% | $62.89 / $42.52 | $9.07 |
| 2. | Medicus Pharma Ltd. | $0.34 | — | $13.54 M | — | -27863.04% | -29.81% | $8.94 / $0.29 | $-0 |
| 3. | Pfizer Inc. | $26.9 | 19.83 | $152.79 B | 6.25% | 10.17% | 8.89% | $28.75 / $21.87 | $15.21 |
| 4. | MIRA Pharmaceuticals, Inc. | $1.12 | — | $47.06 M | — | -100.98% | -1.66% | $2.45 / $0.83 | $0.25 |
| 5. | Amgen Inc. | $346.69 | 24.37 | $187.08 B | 2.84% | 13.95% | 1.06% | $391.29 / $261.43 | $16.07 |
| 6. | Merck & Co., Inc. | $112.83 | 15.49 | $278.33 B | 2.9% | 20.37% | 36.88% | $125.14 / $73.31 | $21.26 |
| 7. | Organon & Co. | $9.26 | 12.89 | $2.41 B | 0.86% | 11.7% | 30.56% | $13.24 / $5.69 | $2.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 19.29 B | 17.6 B | 15.56 B | 12.73 B | 13.53 B | — |
| Operating Profit | 8.99 B | 8.39 B | 7.02 B | 5.3 B | 5.68 B | — |
| Net Profit | 6.64 B | 5.58 B | 5.66 B | 2.76 B | 4.41 B | — |
| EPS in Rs | 7.43 | 6.25 | 6.34 | 3.09 | 4.94 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 65.18 B | 45.04 B | 34.12 B | 28.54 B |
| Operating Profit | 29.7 B | 17.04 B | 10.32 B | 8.28 B |
| Net Profit | 20.64 B | 10.59 B | 5.24 B | 6.24 B |
| EPS in Rs | 23.1 | 11.85 | 5.87 | 6.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 112.48 B | 78.72 B | 64.01 B | 49.49 B |
| Total Liabilities | 85.94 B | 64.44 B | 53.14 B | 38.71 B |
| Equity | 26.54 B | 14.27 B | 10.77 B | 10.65 B |
| Current Assets | 55.63 B | 32.74 B | 25.73 B | 18.03 B |
| Current Liabilities | 35.23 B | 28.38 B | 27.29 B | 17.14 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 16.81 B | 8.82 B | 4.24 B | 7.59 B |
| Investing CF | -10.97 B | -9.3 B | -7.15 B | -3.76 B |
| Financing CF | -2.21 B | 1.23 B | 3.5 B | -5.41 B |
| Free CF | 5.96 B | 414 M | -3.15 B | 4.6 B |
| Capex | -10.85 B | -8.4 B | -7.39 B | -2.99 B |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 32% | 19.56% | — | — |
| Earnings Growth % | 102.1% | -16.09% | — | — |
| Profit Margin % | 23.51% | 15.36% | 21.88% | — |
| Operating Margin % | 37.83% | 30.26% | 29.01% | — |
| Gross Margin % | 81.31% | 79.25% | 76.77% | — |
| EBITDA Margin % | 41.75% | 34.73% | 30.34% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-02-13 | $1.73 |
| 2025-11-14 | $1.5 |
| 2025-08-15 | $1.5 |
| 2025-05-16 | $1.5 |
| 2025-02-14 | $1.5 |
Stock Splits
No stock split history available.